Compare Starbucks Corp (SBUX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs BIO-TECHNE Corp — how do they compare? Starbucks Corp trades at $106.73 (market cap $119.30B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Starbucks Corp is far larger — about 10.6× BIO-TECHNE Corp's market cap, and Starbucks Corp pays the higher dividend (2.37%). Which is the better fit depends on your goals.
| SBUX | TECH | |
|---|---|---|
Market Cap | $119.30B | $11.24B |
Volume | 7,493,833 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $108.37 | $72.29 |
52-Week Low | $78.46 | $43.31 |
Enterprise Value | $138.12B | $11.32B |
Dividend Yield | 2.37% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $105.58, up 0.4% today, with a bullish technical signal and recent earnings beats driving momentum. The stock shows strong fundamental recovery with Q2 2026 EPS of $0.85 beating estimates by 29%, while revenue growth and margin expansion support a raised 2026 outlook. Analyst consensus is split evenly between Buy and Hold, with a $113.60 price target suggesting modest upside from current levels.
The outlook is positive as operational improvements and traffic recovery underpin earnings growth, but high valuation multiples (P/E 61) and competitive pressures pose risks. Investor sentiment is cautiously optimistic, focusing on sustained execution of the turnaround strategy amid macroeconomic uncertainties.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
